A share price of Oramed Pharmaceuticals, Inc [ORMP] is currently trading at $2.34, up 0.43%. An important factor to consider is whether the stock is rising or falling in short-term value. The ORMP shares have gain 2.63% over the last week, with a monthly amount glided 4.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oramed Pharmaceuticals, Inc [NASDAQ: ORMP] stock has seen the most recent analyst activity on January 12, 2023, when Canaccord Genuity downgraded its rating to a Hold and also revised its price target to $3 from $30. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on February 18, 2022, and set its price target to $20. On April 20, 2021, Canaccord Genuity initiated with a Buy rating and assigned a price target of $27 on the stock. National Securities started tracking the stock assigning a Buy rating. Alliance Global Partners initiated its recommendation with a Buy and recommended $11 as its price target on December 03, 2020. Aegis Capital started tracking with a Buy rating for this stock on March 11, 2020, and assigned it a price target of $5.50. In a note dated September 11, 2019, Ladenburg Thalmann initiated a Buy rating and provided a target price of $7 on this stock.
Oramed Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $1.82 and $3.09. Oramed Pharmaceuticals, Inc [NASDAQ: ORMP] shares were valued at $2.34 at the most recent close of the market.
Analyzing the ORMP fundamentals
Gross Profit Margin for this corporation currently stands at -0.02% with Operating Profit Margin at -6.84%, Pretax Profit Margin comes in at -11.11%, and Net Profit Margin reading is -12.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.16 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.27 points at the first support level, and at 2.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.38, and for the 2nd resistance point, it is at 2.43.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Oramed Pharmaceuticals, Inc [NASDAQ:ORMP] is 22.24. On the other hand, the Quick Ratio is 22.24, and the Cash Ratio is 4.28. Considering the valuation of this stock, the price to sales ratio is 46.57, the price to book ratio is 0.47 and price to earnings (TTM) ratio is 2.33.
